Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
-
Publication number: 20130303558Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 19, 2012Publication date: November 14, 2013Inventors: May LUKE, James J. DEVLIN
-
Publication number: 20130296421Abstract: The invention provides a compound of formula (I): or a salt thereof, wherein R1-R4 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.Type: ApplicationFiled: September 7, 2011Publication date: November 7, 2013Inventor: Richard H. Ebright
-
Publication number: 20130295173Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.Type: ApplicationFiled: May 7, 2013Publication date: November 7, 2013Inventors: Bernardus N M MACHIELSE, Timothy J. Maines, Bharat M. Mehta, Michael H. Davidson
-
Patent number: 8569362Abstract: The present invention relates to a polyketide molecule of the following formula (I): or a pharmaceutically acceptable salt thereof, where R1 is a hydrogen atom or a (C1-C7) alkyl group, as well as the method of preparation and use thereof, in particular as an anticancer agent.Type: GrantFiled: October 28, 2010Date of Patent: October 29, 2013Assignees: Pierre Fabre Medicament, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Development (IRD)Inventors: Isabelle Carletti, Georges Massiot, Cécile Debitus
-
Publication number: 20130281393Abstract: The present invention provides novel and advantageous materials and methods for preventing and treating viral infection.Type: ApplicationFiled: April 16, 2013Publication date: October 24, 2013Applicants: VERSITECH LIMITED, PURAPHARM COMPANY LIMITEDInventors: ALLAN SIK YIN LAU, LAI HUNG CINDY YANG
-
Publication number: 20130281493Abstract: A method for determining if a subject with cancer or precancerous lesions or a benign tumor, will respond to treatment with an inhibitor selected from the group comprising an inhibitor of one or more enzymes in the mevalonate pathway, an inhibitor of geranylgeranyl transferase, an inhibitor of farnesyl transferase or an inhibitor of squalene synthase, by (i) obtaining a sample of the cancer cells, precancerous cells or benign tumor cells from the subject, (ii) assaying the cells in the sample for the presence of a mutated p53 gene or a mutant form of p53 protein or a biologically active fragment thereof, and (iii) if the cells have the mutated p53 gene or mutant form of the p53 protein, then determining that the subject will respond to treatment with the inhibitor or combinations thereof. Some embodiments are directed to treatment with the inhibitors.Type: ApplicationFiled: October 7, 2011Publication date: October 24, 2013Applicant: The Trustees of The University of Columbia in the City of New YorkInventors: William Allen Freed-Pastor, Carol Prives
-
Patent number: 8557835Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.Type: GrantFiled: December 20, 2007Date of Patent: October 15, 2013Assignee: Warner-Lambert Company, LLCInventors: Charles Larry Bisgaier, Roger Schofield Newton
-
Publication number: 20130267587Abstract: Anhydrous topical gel composition of mupirocin or its salts comprising: a) a lipophilic base selected from the group consisting of petrolatum, medium-chain triglycerides, isopropyl myristate and mixtures thereof; b) a bioadhesive selected from the group comprising polyvinylpyrrolidone and polymethacrylates; and c) a solvent selected from the group comprising ethanol, propanol, and isopropanol; which is stable and shows an increased residence time of the active ingredient in the skin, resulting in an improved clinical effect in the treatment of bacterial skin infections while maintaining the safety profile of the commercial pharmaceutical product.Type: ApplicationFiled: October 19, 2011Publication date: October 10, 2013Inventors: Carlos González Ojer, Beatriz Goñi Allo, Fiona Pastor Fernández, Cayetana Yárnoz De Miguel
-
Publication number: 20130267586Abstract: The present invention provides compounds of the formula Formula I or a salt thereof: and the uses of such compounds for the treatment of a disease or disorder involving oxidative damage, for preventing UV damage to the skin of a mammal and for preventing or reversing the effects of ageing, or for treating or preventing dry skin.Type: ApplicationFiled: October 13, 2011Publication date: October 10, 2013Applicant: ANTOXIS LIMITEDInventors: Donald Barton McPhail, Graeme James Cook, Richard Charles Hartley
-
Publication number: 20130267486Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventor: Prashant SAWANT
-
Publication number: 20130261175Abstract: The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).Type: ApplicationFiled: November 14, 2011Publication date: October 3, 2013Applicant: MERCK PATENT GMBHInventors: Christophe Carola, Tatjana Mueller
-
Publication number: 20130252937Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: ApplicationFiled: March 14, 2013Publication date: September 26, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Matthias ECKHARDT, Sara FRATTINI, Dieter HAMPRECHT, Frank HIMMELSBACH, Elke LANGKOPF, Iain LINGARD, Stefan PETERS, Holger WAGNER
-
Publication number: 20130252989Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20130251664Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Richard T. Lee
-
Publication number: 20130252990Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20130244985Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130244962Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: April 11, 2013Publication date: September 19, 2013Applicant: Merck Frosst Canada Ltd.Inventors: Elise ISABEL, Christopher MELLON, Christian BEAULIEU
-
Patent number: 8536222Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.Type: GrantFiled: March 21, 2012Date of Patent: September 17, 2013Assignee: AlzChem AGInventors: Thomas Gastner, Hans-Peter Krimmer
-
Publication number: 20130237595Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents.Type: ApplicationFiled: September 16, 2011Publication date: September 12, 2013Inventors: Richard H. Ebright, Yon W. Ebright
-
Publication number: 20130236551Abstract: It is described the use of a combination consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA in which the statins are isolated from contact with the alkyl ester of n-3 PUFA by means of a polymeric membrane that can be easily disintegrated in the gastrointestinal medium, for the treatment of cardiovascular diseases.Type: ApplicationFiled: November 30, 2010Publication date: September 12, 2013Applicant: DEFIANTE FARMACEUTICA .S.A.Inventors: Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta
-
Patent number: 8529890Abstract: Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance.Type: GrantFiled: March 23, 2010Date of Patent: September 10, 2013Assignee: NTNU Technology Transfer ASInventors: Kurt Ingar Draget, Catherine Taylor
-
Publication number: 20130225670Abstract: The present disclosure generally provides methods for assessing a subject's responsiveness to a statin therapy, and selection of a statin dose based upon such methods. The disclosure further provides methods for treating asthma by administering a statin therapy.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: Children's Hospital & Research Center OaklandInventor: Children's Hospital & Research Center Oakland
-
Publication number: 20130225671Abstract: Seizure disorders are treated by Ras inhibitors. In an embodiment, the Ras inhibitor includes a farnesyl transferase inhibitor. In another embodiment, the farnesyl transferase inhibitor includes a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor. In another embodiment, the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor is not a Ras inhibitor. Subjects having fragile X syndrome, autism, Angelman syndrome, Costello syndrome, cardio facio cutaneous syndrome, neurofibromatosis type I, Noonan syndrome and Coffin-Lowry syndrome that have seizure disorders can be treated.Type: ApplicationFiled: April 12, 2013Publication date: August 29, 2013Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Publication number: 20130216560Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: June 20, 2011Publication date: August 22, 2013Applicant: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
-
Publication number: 20130217660Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.Type: ApplicationFiled: May 12, 2011Publication date: August 22, 2013Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
-
Publication number: 20130210778Abstract: This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.Type: ApplicationFiled: March 13, 2013Publication date: August 15, 2013Inventors: Nicholas J. Wald, Malcolm R. Law
-
Patent number: 8505730Abstract: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2013Assignee: JR Chem, LLCInventors: Jose E. Ramirez, Joseph R. Faryniarz
-
Publication number: 20130203727Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).Type: ApplicationFiled: July 1, 2011Publication date: August 8, 2013Applicant: GILEAD SCIENCES, INC.Inventors: Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
-
Patent number: 8501698Abstract: The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.Type: GrantFiled: March 16, 2011Date of Patent: August 6, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Jack Z. Gougoutas, Hildegard Lobinger, Srividya Ramakrishnan, Prashant P. Deshpande, Jeffrey T. Bien, Chiajen Lai, Chenchi Wang, Peter Riebel, John Anthony Grosso, Alexandra A. Nirschl, Janak Singh, John D. DiMarco
-
Patent number: 8501759Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.Type: GrantFiled: December 31, 2009Date of Patent: August 6, 2013Assignee: Fournier Laboratories Ireland LimitedInventor: Eric Bruckert
-
Patent number: 8501968Abstract: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.Type: GrantFiled: June 29, 2011Date of Patent: August 6, 2013Assignee: PharmaMar, S.A.Inventors: Ma Jesús Martin López, Laura Coello Molinero, José Fernando Reyes Benítez, Alberto Rodríguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Andrés Francesch Solloso, Francisco Sánchez Sancho, Maria del Carmen Cuevas Marchante, Rogelio Fernández Rodríguez
-
Publication number: 20130195926Abstract: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.Type: ApplicationFiled: December 4, 2012Publication date: August 1, 2013Applicant: The General Hospital CorporationInventor: The General Hospital Corporation
-
Publication number: 20130195769Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.Type: ApplicationFiled: March 11, 2013Publication date: August 1, 2013Applicant: FOAMIX LTD.Inventor: Foamix Ltd.
-
Publication number: 20130197073Abstract: The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.Type: ApplicationFiled: October 11, 2011Publication date: August 1, 2013Applicant: NEURON BIOPHARMA, S.A.Inventors: Javier Santos Burgos Muñoz, Carlos Ramírez Moreno, Saleta Sierra Ávila, Maria del Carmen Ramos Martín, Juan María Alfaro Sánchez, José Luis Adrio Fondevila, Javier Velasco Alvarez
-
Publication number: 20130189383Abstract: The present invention relates to a method for inhibition of xanthine oxidase comprising administrating an effective amount of the extracts from Acacia spp.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: NATIONAL TAIWAN UNIVERSITYInventor: NATIONAL TAIWAN UNIVERSITY
-
Publication number: 20130184218Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: ApplicationFiled: July 19, 2012Publication date: July 18, 2013Inventors: Dennis J. Paul, Harry J. Gould
-
Patent number: 8486374Abstract: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.Type: GrantFiled: January 14, 2008Date of Patent: July 16, 2013Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Alex Besonov, David Schuz, Tal Berman, Jorge Danziger, Rita Keynan, Ella Zlatkis
-
Publication number: 20130177643Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.Type: ApplicationFiled: January 4, 2013Publication date: July 11, 2013Applicants: Chrysalis Pharma AG, Omthera Pharmaceuticals, Inc.Inventors: Omthera Pharmaceuticals, Inc., Chrysalis Pharma AG
-
Publication number: 20130178446Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: Medicis Pharmaceutical CorporationInventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
-
Patent number: 8481591Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.Type: GrantFiled: November 1, 2010Date of Patent: July 9, 2013Assignee: Stiefel Research Australia Pty. Ltd.Inventor: Prashant Sawant
-
Patent number: 8481570Abstract: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.Type: GrantFiled: June 11, 2012Date of Patent: July 9, 2013Assignee: Cortria CorporationInventors: Robert Bender, Stefan Chlopicki, Jerzy Gebicki
-
Publication number: 20130171079Abstract: A novel composition is disclosed to provide stable kojic acid in a cosmetically or pharmaceutically acceptable medium using a synergistic combination of a sulphur dioxide releasing agent such as sodium metabisulphite and one or more catalases, catalase mimetics, superoxide dismutases, and superoxide dismutase mimetics.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Applicant: Pangaea Laboratories Ltd.Inventors: Elliot Isaacs, Daniel Isaacs
-
Patent number: 8476314Abstract: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.Type: GrantFiled: September 2, 2011Date of Patent: July 2, 2013Assignee: Technology Commercialization CorpInventors: Boris Vladimirovich Krylov, Ilya Vyacheslavovich Rogachevsky, Vera Borisovna Plakhova
-
Patent number: 8475840Abstract: The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels.Type: GrantFiled: April 8, 2005Date of Patent: July 2, 2013Assignee: Hanmi Science Co., LtdInventors: Jong Soo Woo, Hong-Gi Yi, Moon-Hyuk Chi, Jae-Kuk Ryu, Si-Young Jung, Yong-Il Kim
-
Patent number: 8476259Abstract: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.Type: GrantFiled: September 12, 2012Date of Patent: July 2, 2013Assignee: Asahi Kasei Pharma CorporationInventor: Benson Fong
-
Publication number: 20130165505Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for improving Cognitive Function; treating Cognitive Impairment, in particular Mild Cognitive Impairment; and preventing and/or reducing the risk of developing Alzheimer's Disease in a cognitively normal subject.Type: ApplicationFiled: December 21, 2012Publication date: June 27, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130165368Abstract: A composition for use in the prevention and/or treatment of microbial infection comprising essentially of one or more pure alkanol alkoxylates, diol alkoxylates and/or triol alkoxylates.Type: ApplicationFiled: February 1, 2011Publication date: June 27, 2013Inventors: Ian Steel, Paul Armstrong
-
Publication number: 20130158058Abstract: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.Type: ApplicationFiled: February 14, 2013Publication date: June 20, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: The Trustees of the University of Pennsylvania
-
Publication number: 20130150393Abstract: A composition for increasing the bioavailability of a statin active pharmaceutical ingredient (“API”) in humans and animals, wherein that composition includes a statin API selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: ApplicationFiled: December 12, 2012Publication date: June 13, 2013Applicant: PRUGEN IP HOLDINGS, INC.Inventor: Prugen IP Holdings, Inc.
-
Publication number: 20130131088Abstract: The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.Type: ApplicationFiled: January 13, 2011Publication date: May 23, 2013Applicant: UNIVERSITY HEALTH NETWORKInventors: Linda Penn, Aaron Schimmer, Aleksandra Pandyra